29 research outputs found

    Entangled Quantum Clocks for Measuring Proper-Time Difference

    Full text link
    We report that entangled pairs of quantum clocks (non-degenerate quantum bits) can be used as a specialized detector for precisely measuring difference of proper-times that each constituent quantum clock experiences. We describe why the proposed scheme would be more precise in the measurement of proper-time difference than a scheme of two-separate-quantum-clocks. We consider possibilities that the proposed scheme can be used in precision test of the relativity theory.Comment: no correction, 4 pages, RevTe

    Prominent bulk pinning effect in the MgB_2 superconductor

    Full text link
    We report the magnetic-field dependence of the irreversible magnetization of the recently discovered binary superconductor MgB2_{2}. For the temperature region of T<0.9TcT< 0.9T_c, the contribution of the bulk pinning to the magnetization overwhelms that of the surface pinning. This was evident from the fact that the magnetization curves, M(H)M(H), were well described by the critical-state model without considering the surface pinning effect. It was also found that the M(H)M(H) curves at various temperatures scaled when the field and the magnetization were normalized by the characteristic scaling factors H(T)H^\ast(T) and M(T)M^\ast(T), respectively. This feature suggests that the pinning mechanism determining the hysteresis in M(H)M(H) is unique below T=TcT=T_c.Comment: 4pages and 4 figures. Phys. Rev. B (accepted

    Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

    Get PDF
    Background:Antiretroviral regimens with simplified dosing and better safety are needed to maximize the efficiency of antiretroviral delivery in resource-limited settings. We investigated the efficacy and safety of antiretroviral regimens with once-daily compared to twice-daily dosing in diverse areas of the world.Methods and Findings:1,571 HIV-1-infected persons (47% women) from nine countries in four continents were assigned with equal probability to open-label antiretroviral therapy with efavirenz plus lamivudine-zidovudine (EFV+3TC-ZDV), atazanavir plus didanosine-EC plus emtricitabine (ATV+DDI+FTC), or efavirenz plus emtricitabine-tenofovir-disoproxil fumarate (DF) (EFV+FTC-TDF). ATV+DDI+FTC and EFV+FTC-TDF were hypothesized to be non-inferior to EFV+3TC-ZDV if the upper one-sided 95% confidence bound for the hazard ratio (HR) was ≤1.35 when 30% of participants had treatment failure.An independent monitoring board recommended stopping study follow-up prior to accumulation of 472 treatment failures. Comparing EFV+FTC-TDF to EFV+3TC-ZDV, during a median 184 wk of follow-up there were 95 treatment failures (18%) among 526 participants versus 98 failures among 519 participants (19%; HR 0.95, 95% CI 0.72-1.27; p = 0.74). Safety endpoints occurred in 243 (46%) participants assigned to EFV+FTC-TDF versus 313 (60%) assigned to EFV+3TC-ZDV (HR 0.64, CI 0.54-0.76; p<0.001) and there was a significant interaction between sex and regimen safety (HR 0.50, CI 0.39-0.64 for women; HR 0.79, CI 0.62-1.00 for men; p = 0.01). Comparing ATV+DDI+FTC to EFV+3TC-ZDV, during a median follow-up of 81 wk there were 108 failures (21%) among 526 participants assigned to ATV+DDI+FTC and 76 (15%) among 519 participants assigned to EFV+3TC-ZDV (HR 1.51, CI 1.12-2.04; p = 0.007).Conclusion: EFV+FTC-TDF had similar high efficacy compared to EFV+3TC-ZDV in this trial population, recruited in diverse multinational settings. Superior safety, especially in HIV-1-infected women, and once-daily dosing of EFV+FTC-TDF are advantageous for use of this regimen for initial treatment of HIV-1 infection in resource-limited countries. ATV+DDI+FTC had inferior efficacy and is not recommended as an initial antiretroviral regimen.Trial Registration:http://www.ClinicalTrials.gov NCT00084136
    corecore